Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 10 de 10
Filter
Add filters








Year range
1.
Article in Chinese | WPRIM | ID: wpr-1029766

ABSTRACT

Objective:To evaluate the efficacy and safety of comprehensive treatment for retinoblastoma (RB).Methods:A retrospective clinical study. From January to December in 2019, 157 cases (203 eyes) of RB who were diagnosed by the Department of Ophthalmology of Xinhua Hospital and received comprehensive treatment were included in this study. Of cases, 76 were male, and 81 were female; 111 were unilateral, and 46 were bilateral. The medium of age at diagnosis was 20.1 months. All patients received treatment for the first time. Patients with intraocular tumors were divided into A-E stages, extraocular stage and distant metastasis according to international intraocular RB classification standard. The median follow-up time was 37.4 months. Clinical features, treatment, prognosis and ocular complications of all cases were recorded.Results:Among 157 cases (203 eyes), 137 cases (180 eyes) were in intraocular stage; 6, 14, 10, 98, and 52 of eyes were in A-E stages, respectively. Twelve cases (12 eyes) were in extraocular stage; 8 cases (11 eyes) were in distant metastasis stag; 8 cases died due to distant metastasis; 149 cases (94.9%, 149/157) survived; 48 eyes were enucleated, 34 of which underwent initial enucleation, and 14 eyes underwent enucleation after eye-preserving treatment. The overall global salvage rate was 155 eyes (76.4%,155/203), and that after eye-preserving treatment was 91.7% (155/169). Severer eye for bilateral cases was taken into account for statistic; 120 cases (120 eyes) received initial eye-preserving treatment. Among them, 36 and 84 eyes underwent initial intravenous chemotherapy (IVC) and initial intra-arterial chemotherapy (IAC), respectively. The enucleation of the two groups was 7(19.4%, 7/36), 7(8.3%, 7/84); 33 (91.7%, 33/36) and 33 (39.3%, 33/84) eyes received the second treatment, respectively. There was no significant difference in the rate of enucleation between the two treatments ( χ2=2.037, P=0.154). There was significant difference in the percentage of secondary treatment ( χ2=27.937, P<0.001). Fifty-four eyes (45.0%, 54/120) stabilized after initial treatment, and 66 eyes (55.0%, 66/120) underwent secondary treatments due to poor response or tumor recurrence. For 66 eyes receiving secondary treatments, enucleation, IAC, intravitreous chemotherapy (IVitC), IAC combined with IVitC, and laser and/or cryotherapy was performed in 6, 18, 12, 13, and 17 eyes, respectively. The number of eyes of enucleation among the IAC, IVitC, and IAC combined with IVitC group was 5 (27.8%, 5/18), 1 (9.3%, 1/12), and 2 (15.4%, 2/13) eyes, which was no significantly different ( χ2=2.001, P=0.368). Until the last follow-up, visual acuity outcomes were acquired in 148 eyes (72.9%, 148/203). Among them, 41, 53, 16 and 38 eyes had no light perception, light perception to finger counting, 20/400, and ≥20/200, respectively. In total, among 203 eyes, 121 eyes received IAC, of which 2, 4, and 1 eyes had optic disc atrophy, vitreous hemorrhage, and severe retinal-choroidal atrophy, respectively; 60 eyes received IVitC, of which one and one eye had vitreous hemorrhage and macular hemorrhagic necrosis, respectively. Conclusions:In this study, the overall survival rate was 94.9% after comprehensive treatment and the rate of global salvage after eye-preserving treatment was 91.7%. The comprehensive treatment of retinoblastoma had a relatively high efficacy and safety.

2.
Chinese Journal of Urology ; (12): 578-580, 2017.
Article in Chinese | WPRIM | ID: wpr-610933

ABSTRACT

Objective To study the efficacy and safety of intravesical chemotherapy combined with intravenous chemotherapy for high grade T1 (T1G3) bladder cancer after transurethral resection of bladder tumor(TURBT).Methods From January 2012 to December 2015,111 patients with high grade T1 (T1 G3) bladder cancer were retrospectively reviewed.Thirty-six patients received TURBT and intravesical chemotherapy and intravenous chemotherapy (group A),75 patients received TURBT and intravesical chemotherapy(group B).In group A,there were 28 males and 8 females,with average age 66.2 years;in group B,there were 59 males and 16 females,with mean age 67.9 years.There was no statistical difference between the two groups in age,sex,smoking history,tumor diameter,tumor number.1-year recurrence-free survival (RFS),1-year progression-free survival (PFS),intravenous chemotherapy adverse reaction were analyzed.Results All the patients were followed-up for 12 months.9 patients relapsed in group A,1-year RFS rate 75%,and the median RFS of the 9 patients was 9 (3-11) months.36 patients relapsed in group B,1-year RFS rate 52%,and the median RFS of the 36 patients was 7 (3-11) months.There was statistically significant difference between the two group(P =0.02).One patient progressed in group A,1-year PFS rate 97.2%,and the PFS was 9 months.Six patients progressed in group B,1-year PFS rate 92%,and the median PFS was 9.5(6-12) months.There was no statistically significant difference (P =0.305) between the two group.Only 1 case (3%) appeared Ⅲ° or above intravenous chemotherapy adverse reaction.Conclusions Intravesical chemotherapy combined with intravenous chemotherapy offers a better RFS rate than the intravesical chemotherapy alone for patients with T1G3 bladder cancer after TURBT,and there are very low rates of serious side effects.Intravenous chemotherapy may be considered as a new therapy strategy for T1G3 bladder cancer after TURBT.

3.
Article in Chinese | WPRIM | ID: wpr-511594

ABSTRACT

Objective To explore the clinical efficacy of cisplatin intraperitoneal perfusion combined with intravenous chemotherapy in the treatment of advanced gastric cancer.Methods 82 cases of patients with advanced gastric cancer were divided into two groups according to the random number table method: 41 cases of observation group were given cisplatin intraperitoneal perfusion combined with intravenous chemotherapy,41 cases in the control group received intravenous chemotherapy alone.To observe the short-term curative effect and adverse reaction.Results The total efficiency of treatment group were 46.35%(19/41)and the control group 26.83%(11/41),difference between the two groups was statistically significant(P< 0.05); the adverse reactions of the two groups of patients occurrence had no significant difference.Compared with the control group,the IgA and IgG in the observation group were significantly higher than that in the control group after treatment,the difference was significant(P<0.05); there was no significant difference between the IgM group and the control group before and after treatment.Conclusion Intraperitoneal perfusion combined with intravenous chemotherapy in patients with advanced gastric cancer can significantly improve the treatment effect,without increasing adverse reactions,it is worth popularizing.

4.
China Journal of Endoscopy ; (12): 67-71, 2017.
Article in Chinese | WPRIM | ID: wpr-621129

ABSTRACT

Objective To study the influence of laparoscopic radiofrequency ablation combined with intravenous chemotherapy on hepatoma cell growth mediated by PTEN and Wnt pathway. Methods 90 cases of hepatocellular carcinoma patients from May 2013 to June 2016 were chosen as study subjects, all patients were divided into observation group (n = 45), control group (n = 45) randomly. Patients in observation group received laparoscopic radiofrequency ablation combined with intravenous chemotherapy, while those in control group received intravenous chemotherapy only. One week after treatment, two groups patients' liver lesion tissue PTEN signaling pathway, Wnt signaling pathway related gene mRNA expression were detected by RT-PCR method; serum contents of tumor markers were tested by Radioimmunoassay. Results One week after treatment, liver lesion tissue PTENmRNA expression was higher in observation group than that in control group, HIF-1, VEGF mRNA expression were lower in observation group than those in control group, the difference was statistically significant (P < 0.05); liver lesion tissue Wnt pathway related genes mRNA expression such as β-catenin, CyclinD1, c-myc, MMP-7 were lower in observation group than those in control group, the difference was statistically significant (P < 0.05); serum contents of tumor markers such as AFP, GGT-Ⅱ, IGF-2, CA19-9 were lower in observation group than those in control group, the difference was statistically significant (P < 0.05). Conclusion Laparoscopic radiofrequency ablation combined with intravenous chemotherapy can inhibit the growth of HCC cells through the PTEN and Wnt pathway, which has positive clinical significance.

6.
Tianjin Medical Journal ; (12): 1180-1182,1249, 2014.
Article in Chinese | WPRIM | ID: wpr-600043

ABSTRACT

Objective To compare the inhibiting effect on human lung adenocarcinoma who were treated with gem?citabine combined with cisplatin chemotherapy through either arterial or intravenous route to explore the optimum adminis?tration route. Methods Human lung adenocarcinoma derived A549 cells were transplanted into 40 BALB/c-nu mice to es?tablish lung cancer model. The models were divided into 4 groups:animals in arterial or intravenous chemotherapy groups were treated with gemcitabine 150 mg/kg combined with cisplatin 10 mg/kg through either arterial route or intravenous route. Animals in negative control group were given normal saline through caudal vein while animals in sham operation group were treated with normal saline via arterial route. Then dynamical change of tumor volume and tumor inhibiting rate were assessed , and Bcl-2 and Caspase 3 expressions were investigated using western blot. Finally inhibiting effect were compared between these two different administration routes. Results Transplanted tumors in arterial and intravenous che?motherapy groups (especially in arterial group) were suppressed, in terms of mass of tumor(g:1.91±0.19, 2.61±0.21 vs 4.58± 0.46), compared to the control group (P<0.05). Furthermore, tumor inhibiting rates in arterial chemotherapy group and ve?nous chemotherapy group are 57.6%and 42.4%respectively (P<0.05). Expression of Bcl-2 was down regulated while ex?pression of Caspase-3 was up regulated upon both arterial and intravenous chemotherapy. And arterial route showed much more obvious tumor apoptosis effect than venous route. Conclusion Arterial route of gemcitabine combined with cisplatin for lung adenocarcinoma treatment is more effective to restrain the tumor growth in clinical application.

7.
Article in Chinese | WPRIM | ID: wpr-555418

ABSTRACT

AIM: To evaluate the efficacy and safety on the radio-heating-chemotherapy in treatment of patients with malignant pleural effusion (MPE). METHODS: 60 patients of MPE were randomly devided into two groups, radio-chemotherapy group (treatment group) and chemotherapy group (control group). The drugs, according to the types of tumor cells, were select to take intravenous injection and pleural cavity administration. The patient’s pleural cavity was drained continuously by pleurocentesis. These treatments were made once two week lasting for 4-6 weeks with NS 30 ml+cisplatin 60 mg by perfusion of pleural cavity. After the perfusin of pleural cavity, radio-heating was performed 60-90 min, twice one week for 8-10 times in the treatment group. RESULTS: The response rate was 90% (CR+PR) in the treatment group, and 67% (CR+PR) in the control group. The rates were higher than those in the control group (P

8.
China Oncology ; (12)2000.
Article in Chinese | WPRIM | ID: wpr-540541

ABSTRACT

Purpose:To evaluate the efficacy and toleranc e of radiofrequency chemohyperthermia combined with intravenous chemotherapy for m alignant ascites. Methods:Twenty patients with malignant ascites received the tre atment .After abdominal cavity aspiration and infusion of hot 0.9% sodium chlori de injection 1 500-2 000 ml with 5-FU , Estimated the temperature of abdominal cavity was estimated with a sensor, then treated with SR-1000 radiofrequency h yperthermia for 70 minutes and chemotherapy at the same time.The radiofrequency chemohyperthermia with 5-FU 0.5-1.0 g was given d 1,4,8,11 and intravenous che motherapy with oxaliplatin 100 mg was given d 1,8 or cisplatin 40-60 mg d 1,8. Results:The average treatment temperature was 41.5℃ in 20 case s. The highest was 43.5℃ and lowest temperature was 40.5℃. The response rate o f ascites was 90%(18/20) The response rate of peritoneo-pelvic tumor was 58.8%( 10/17).1-year overall survival rate is 75%. The common side-effects were fat n ecrosis (20%) and adominal pain (25%). Conclusions:Radiofrequency chemohyperthermia combined with intr avenous chemotherapy appears to have a relatively high response with low side-e ffects for malignant ascites and good response for peritoneo-pelvic malignant t umors.

9.
China Oncology ; (12)2000.
Article in Chinese | WPRIM | ID: wpr-542285

ABSTRACT

Purpose:To study the intraperitonal chemotherapy combined with intravenous chemotherapy after surgery for the treatment of ovarian cancer. Methods:The 88 patients of ovarian cancer after cytoreductive surgery were divided into two groups A and B. A group(45 cases) received intraperitonal chemotherapy three times once a week with DDP and 5-FU plus either the MMC or AT-1258, then intravenous chemotherapy, stages Ⅰ/Ⅱ 21 cases(23.86%),stages Ⅲ/Ⅳ 24 cases(27.27%). B groups were given intravenous chemotherapy with CAP protocol once every three weeks,stage Ⅰ/Ⅱ 24 cases(27.27%),stages Ⅲ/Ⅳ 19 cases(21.59%).Results:After three or six courses of chemotherapy there was significant decrease in CA125 both Ⅰ/Ⅱ and Ⅲ/Ⅳ in A and B groups . After three courses of chemotherapy there were 34 cases((38.64%))of A groups and 19 cases(21.59%)of the B groups with CA12535 u/ml(35 cases) who were given three courses of chemotherapy after entire treatment. A and B groups in the Ⅰ/Ⅱ stages showed average survival time (35.05?0.54),(32.38?1.19) months,and in the Ⅲ/Ⅳ stages showed average survival time (31.33?1.41),(28.26?1.88) months.There was no significance (P=0.156) with three year survival rate between A and B groups in the Ⅰ/Ⅱ stages with Log Rank test. There was no significance (P=0.08) in three-year survival rate between A and B groups in the Ⅲ/Ⅳ stages with Log Rank test. There was significance in three-year survival rate between A and B with intraperitonal fluid.Conclusions:The intraperitonal chemotherapy combined with intravenous chemotherapy after surgery for the treatment of ovarian cancer could marketly decrease CA125 than intravenous chemotherapy after three or six courses. Three-year survival ratewas significantly different between CA125 35 u/ml(35 cases) when they were given three courses of chemotherapy after entire treatment. Although the intraperitonal chemotherapy after surgery for the treatment of ovarian cancer had no significant difference between A and B groups in Ⅰ/Ⅱ and Ⅲ/Ⅳ stages with three-year survival rate , it appears longer survival time . There is significant difference with three-year survival between A and B with intraperitonal fluid. The intraperitional chemotherapy combined with intravenous chemotherapy after surgery can be used for the ovarian cancer with intraperitonal fluid and metastases.

10.
China Oncology ; (12)1998.
Article in Chinese | WPRIM | ID: wpr-675076

ABSTRACT

Purpose:To evaluate the immediate therapeutic effects and toxicities of intraperitoneal versus intravenous chemotherapy in advanced gastric cancer.Methods:Sixty one patients were treated with intravenous chemotherapy of leucovorin (CF) , fluorouracil ( 5 Fu) etoposide (Vp16) and intraperitoneal chemotherapy of cis platinum (DDP) in advanced gastric cancer. The short term effects and toxicities were observed.Results:The overall response rate was 57.4% and the complete response rate was 9.8% of the 61 patients .Leukopenia was observed in 95.1%, thrombocy topentia were observed in 27.8% of patients . Other side effects were uncommon.Conclusions:Intravenous chemotherapy of ELF and intraperitoneal chemotherapy of DDP were effective for advanced gastric cancer and are worthy to be further studied.

SELECTION OF CITATIONS
SEARCH DETAIL